Skip to main content
. 2014 Sep 17;5:33–41. doi: 10.4137/JCM.S16585

Table 3.

Changes in secondary endpoints from baseline to week 24.

PARAMETER LIRAGLUTIDE SITAGLIPTIN P-VALUE
n* CHANGE FROM BASELINE P-VALUE n* CHANGE FROM BASELINE P-VALUE
Body weight (kg) 36 −0.60 ± 2.44 0.1513 38 0.29 ± 2.05 0.3848 0.0969
BMI (kg/m2) 36 −0.23 ± 0.98 0.167 38 0.11 ± 0.78 0.3784 0.1027
FPG (mg/dL) 46 −21.15 ± 31.22 <0.0001 41 0.46 ± 39.39 0.9403 0.0014
F-IRI (μU/mL) 46 0.68 ± 3.39 0.183 42 1.46 ± 9.35 0.3178 0.5771
F-proinsulin (μU/mL) 46 1.06 ± 16.79 0.671 42 2.75 ± 20.64 0.393 0.683
HOMA-R 46 −0.17 ± 1.54 0.4619 41 1.12 ± 7.07 0.3166 0.2108
HOMA-β 46 26.18 ± 73.64 0.02 41 6.01 ± 33.75 0.2612 0.0944
Proinsulin/insulin ratio 46 −0.26 ± 2.28 0.4377 42 −1.07 ± 6.64 0.3008 0.7114
CPR (ng/mL) 46 0.21 ± 0.50 0.0073 42 0.09 ± 0.93 0.5277 0.4162
NT-proBNP (pg/mL) 46 −6.91 ± 42.04 0.2707 42 1.05 ± 60.71 0.9115 0.6202
Log-hsCRP 46 0.01 ± 1.40 0.9631 42 0.26 ± 1.18 0.1603 0.7435
PAID total score 39 −2.41 ± 7.97 0.1026 35 −2.97 ± 15.67 0.2829 0.7286

Notes:

*

The number of patients differs between each parameter because data are shown only for patients with data for the individual parameter at Week 24 and the last observation was not carried forward to impute missing data.

Versus baseline (paired t-test, except PAID total score [Wilcoxon signed-rank test]).

For liraglutide versus sitagliptin (ANCOVA, except PAID total score [Wilcoxon rank-sum test]). Values are means ± standard deviation.

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; F-IRI, fasting immunoreactive insulin; F-proinsulin, fasting proinsulin; HOMA-R, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β cell function; CPR, C-peptide immunoreactivity; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; PAID, problem areas in diabetes survey.